Search

NOVA University and Max Delbrück Center are jointly establishing the NOVA Institute for Medical Systems Biology (NIMSB). Both institutions have developed a shared vision to push the boundaries of precision medicine. “Insights” spoke to the three project leads in Lisbon and Berlin.

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant.

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.

The Berlin biotech Glycotope and the Max Delbrück Center have signed an agreement to explore the potential of combining Glycotope’s tumor-specific antibodies with CAR technology developed by the Max Delbrück Center. Their common goal: advancing immunotherapies against solid tumors.

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable.

Internationally renowned for pioneering achievements and geared to inter-institutional cooperation: 22 research groups at the Berlin Institute for Medical Systems Biology in the Max Delbrück Center (MDC-BIMSB) explore how genes regulate life. It is now celebrating its 15th birthday.

While CAR-T cells have proven successful in treating certain types of leukemia and lymphoma, these immunotherapies can become even more effective. A clinical trial run by Charité and the Max Delbrück Center has been awarded a grant of several million euros to test a new approach.

Innovative biomedical research requires cutting-edge technologies, good ideas and a wealth of expertise. To ensure that technology platforms and research teams at the MDC make optimal use of investments and new equipment, Jutta Steinkötter initiated 13 “tandems” in late 2022 and awarded them a total of €300,000.

Six sites are now collaborating with the Deutsches Krebsforschungszentrum (German Cancer Research Center) in the National Center for Tumor Diseases (NCT). In Berlin, a central partner is the Charité – Universitätsmedizin Berlin, in close cooperation with the Berlin Institute of Health at the Charité (BIH) and the Max Delbrück Center.

Mikhail Kudryashev's scientific career has been defined by his intensive work on the structure of proteins, those tiny building blocks of life. He has now been appointed to a Heisenberg Professorship at the Charité as of August 1, 2022.